Skip to main content
Equibles
OCUL logo

OCUL · Ocular Therapeutix, Inc · Metrics

Track OCUL — free

Use OCUL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research OCUL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$7.14 +0.32 (+4.69%) At close · Nov 4 Play latest call Q1 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$1.54B
Shares
219.62M
Volume · Nov 4 3.36M Avg daily vol (3M) 3.04M

OCUL metrics

81 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$7.14
Market cap
$1.54B

Price action

20 metrics
Price change (1W)
+1.5%
Price change (30D)
-5.9%
Price change (3M)
-20.6%
Price change (6M)
-29.8%
Price change (YTD)
-43.8%
Price change (1Y)
-40.2%
Trailing year
Price change (5Y)
-5.0%
52-week high
$16.11
52-week low
$6.29
Change from 52-week high
-57.7%
Change from 52-week low
+8.4%
Annualized volatility
75.2%
Annualized volatility (3M)
71.7%
Beta
1.3
RSI (14D)
41.1
Price vs SMA 50
-21.1%
Price vs SMA 200
-24.8%
Avg volume (3M)
3.03M
Relative volume
0.7
Average dollar volume
$26.48M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
219.62M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
19.6×
reciprocal yield 5.1%
EV / EBITDA
—
EV / EBIT
—
P / sales
29.7×
reciprocal yield 3.4%
P / book
3.0
reciprocal yield 33.7%
FCF yield
-16.5%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-19.5%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
19.1×
reciprocal yield 5.2%
EV / revenue historical average (5Y)
15.1×
reciprocal yield 6.6%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-09
Last earnings
2026-08-18

Profitability

9 metrics
Gross margin
87.1%
Operating margin
-603.0%
Trailing 12 months
Net margin
-579.1%
Gross profit (TTM)
$45.35M
Operating profit (TTM)
−$313.91M
Net income (TTM)
−$301.45M
Trailing 12 months
Diluted EPS (TTM)
$-1.40
FCF margin
-490.1%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$3.03

Growth

11 metrics
Revenue growth YoY
+0.1%
Year over year
Net income growth YoY
—
Revenue (TTM)
$52.05M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+30.3%
Year over year · more shares
Revenue CAGR (3Y)
+0.3%
Revenue CAGR (5Y)
+24.4%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-58.0%
Return on assets
-44.9%
Debt / equity
0.1
Current ratio
13.1
EBITDA (TTM)
−$308.46M
Free cash flow (TTM)
−$255.10M
Quick ratio
13.0
Interest coverage
-27.5
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$525.85M
Latest balance sheet
Cash & equivalents
$598.64M
Total assets
$671.32M
Total debt
$72.80M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$238.24M
Capital expenditures (TTM)
$16.86M
R&D (TTM)
$223.51M
SG&A (TTM)
—
Stock compensation (TTM)
$53.28M
R&D / revenue
429.4%
Stock compensation / revenue
102.4%

Ownership (13F)

9 metrics
13F filers
264
13F filer change QoQ
-11
Institutional ownership
95.5%
Conviction holders (share of 13F filers)
2.3%
Crowding (high-turnover and private-fund holders)
32.1%
Private-fund adviser ownership
30.8%
Active holders' share change QoQ
-3.4%
Holder tenure
13.4
Price vs estimated holder cost
+12.3%

Ownership (registered funds)

1 metrics
Index-fund ownership
12.8%

Short interest

3 metrics
Short interest
13.1%
Latest settlement · 8.1 days to cover
Days to cover
8.1d
Short-squeeze score
73 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$567,500
Insider-sentiment score
57 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1393434 CUSIP 67576A100 13F (30d) 65 filings 65 filers Visit website Investor relations